Journal of International Oncology››2014,Vol. 41››Issue (8): 648-651.doi:10.3760/cma.j.issn.1673422X.2014.09.003
Previous ArticlesNext Articles
Zhang Xintong, Yue Wentao
Online:
2014-09-25Published:
2014-09-05Contact:
Yue Wentao E-mail:yuewt2000@yahoo.comZhang Xintong, Yue Wentao. Alternative splicing of tumor associated genes messenger RNA and application[J]. Journal of International Oncology, 2014, 41(8): 648-651.
[1] Gilbert W. Why genes in pieces?[J]. Nature, 1978, 271(5645): 501. [2] Berget SM, Moore C, Sharp PA. Spliced segments at the 5′ terminus of adenovirus 2 late mRNA[J]. Proc Natl Acad Sci USA, 1977, 74(8): 3171-3175. [3] Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes[J]. Nature, 2008, 456(7221): 470-476. [4] Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3[J]. Nat Genet, 2000, 25(3): 315-319. [5] Foley CJ, Freedman H, Choo SL, et al. Dynamics of RASSF1A/MOAP1 association with death receptors[J]. Mol Cell Biol, 2008, 28(14): 4520-4535. [6] Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20like kinases MST1 and MST2[J]. J Biol Chem, 2011, 286(8): 6253-6261. [7] Reeves ME, Baldwin ML, Aragon R, et al. RASSF1C modulates the expression of a stem cell renewal gene, PIWIL1[J]. BMC Res Notes, 2012, 5: 239. [8] Reeves ME, Firek M, Chen ST, et al. The RASSF1 gene and the opposing effects of the RASSF1A and RASSF1C isoforms on cell proliferation and apoptosis[J]. Mol Biol Int, 2013, 2013: 145096. [9] Arribas J, Baselga J, Pedersen K, et al. p95HER2 and breast cancer[J]. Cancer Res, 2011, 71(5): 1515-1519. [10] Pedersen K, Angelini PD, Laos S, et al. A naturally occurring HER2 carboxyterminal fragment promotes mammary tumor growth and metastasis[J]. Mol Cell Biol, 2009, 29(12): 3319-3331. [11] Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5): 401-404. [12] Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269): pl1. [13] Valent A, PenaultLlorca F, Cayre A, et al. Change in HER2 (ERBB2) gene status after taxanebased chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management[J]. Cancer Genet, 2013, 206(12): 37-41. [14]Harbeck N, Pegram MD, Rüschoff J, et al. Targeted therapy in metastatic breast cancer: the HER2/neu oncogene[J]. Breast Care (Basel), 2010, 5(s1): 3-7. [15]Jackson C, Browell D, Gautrey H, et al. Clinical significance of HER2 splice variants in breast cancer progression and drug resistance[J]. Int J Cell Biol, 2013, 2013: 973584. [16]Mitra D, Brumlik MJ, Okamgba SU, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance[J]. Mol Cancer Ther, 2009, 8(8): 2152-2162. [17]Marchini C, Gabrielli F, Iezzi M, et al. The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse[J]. PLoS One, 2011, 6(4): e18727. [18]Pedersen K, Angelini PD, Laos S, et al. A naturally occurring HER2 carboxyterminal fragment promotes mammary tumor growth and metastasis[J]. Mol Cell Biol, 2009, 29(12): 3319-3331. [19]Makino H, Iraha M, Manba N, et al. Utility of serum human epidermal growth factor receptor2 extracellular domain(HER2 ECD)assessment in patients with advanced or recurrent breast cancer and those who received neoadjuvant therapy[J]. Gan To Kagaku Ryoho, 2012, 39(2): 237-240. [20]Leary AF, Hanna WM, van de Vijver MJ, et al. Value and limitations of measuring HER2 extracellular domain in the serum of breast cancer patients[J]. J Clin Oncol, 2009, 27(10): 1694-1705. [21]Koletsa T, Kostopoulos I, Charalambous E, et al. A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas[J]. Neoplasia, 2008, 10(7): 687-696. [22]Bauman JA, Li SD, Yang A, et al. Antitumor activity of spliceswitching oligonucleotides[J]. Nucleic Acids Res, 2010, 38(22): 8348-8356. [23]刘艳红, 赵艳洁, 房淑娟, 等. 肝癌相关基因的分子克隆和可变剪切分析[J]. 中南大学学报(医学版), 2013(9): 869-875. [24]Won YS, Lee SW. Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by transsplicing ribozyme[J]. J Biotechnol, 2012, 158(12): 44-49. [25]Choi JW, Kim DG, Lee AE, et al. Cancerassociated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis[J]. PLoS Genet, 2011, 7(3): e1001351. [26]Chang WH, Liu TC, Yang WK, et al. Amiloride modulates alternative splicing in leukemic cells and resensitizes BcrAblT315I mutant cells to imatinib[J]. Cancer Res, 2011, 71(2): 383-392. [27]Wan J, Sazani P, Kole R. Modification of HER2 premRNA alternative splicing and its effects on breast cancer cells[J]. Int J Cancer, 2009, 124(4): 772-777. [28]Wang Y, Cheong CG, Hall TM, et al. Engineering splicing factors with designed specificities[J]. Nat Methods, 2009, 6(11): 825-830. [29]Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth[J]. Nature, 2008, 452(7184): 230-233. |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[5] | Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353. |
[6] | Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[7] | Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[8] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[9] | Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[10] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[11] | Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[12] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[13] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[14] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[15] | Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||